Biosimilars: After FDA's Public Meeting, Is A Payer Summit Needed Too?
Executive Summary
FDA may be forced to campaign for support of its biosimilar decisions in the health care community to ensure entities like hospital Pharmacy and Therapeutics Committees embrace the products.